{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:06:07Z","timestamp":1779444367102,"version":"3.53.1"},"reference-count":23,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/wdog7321","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T03:22:57Z","timestamp":1765768977000},"page":"9209-9220","source":"Crossref","is-referenced-by-count":0,"title":["Long-term efficacy of adalimumab in elderly patients with rheumatoid arthritis and associated risk factors"],"prefix":"10.62347","volume":"17","author":[{"given":"Aiping","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1083879","DOI":"10.3389\/fmed.2022.1083879","article-title":"polymyalgia rheumatica: differences in pathogenesis","volume":"9","author":"Wu","year":"2023","unstructured":"Wu J, Yang F, Ma X, Lin J and Chen W. Elderly-onset rheumatoid arthritis vs. polymyalgia rheumatica: differences in pathogenesis. Front Med (Lausanne) 2023; 9: 1083879.","journal-title":"Front Med (Lausanne)"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Abid A, Nawaz U and Sunmboye KO. Hypertrophic osteoarthropathy mimicking rheumatoid arthritis. Cureus 2024; 16: e71153.","DOI":"10.7759\/cureus.71153"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"MacDonald L, Elmesmari A, Somma D, Frew J, Di Mario C, Madhu R, Paoletti A, Simakou T, Hardy OM, Tolusso B, Campobasso D, Perniola S, Gessi M, Gigante MR, Petricca L, Bruno D, Coletto LA, Benvenuto R, Isaacs JD, Filby A, McDonald D, Sim JPX, Jamieson N, Wei K, D’Agostino MA, Millar NL, Milling S, McSharry C, Gremese E, Affleck K, Baker KF, McInnes IB, Otto TD, Korsunsky I, Alivernini S and Kurowska-Stolarska M. Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity 2024; 57: 2843-2862, e2812.","DOI":"10.1016\/j.immuni.2024.11.004"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"110337","DOI":"10.1016\/j.clim.2024.110337","article-title":"Mechanisms of age-related Treg dysfunction in an arthritic environment","volume":"266","author":"Nishiyama","year":"2024","unstructured":"Nishiyama T, Ohyama A, Miki H, Asashima H, Kondo Y, Tsuboi H, Ohno H, Shimano H and Matsumoto I. Mechanisms of age-related Treg dysfunction in an arthritic environment. Clin Immunol 2024; 266: 110337.","journal-title":"Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40744-020-00267-8","article-title":"Features and outcomes of elderly rheumatoid arthritis: does the age of onset matter? A comparative study from a single center in China","volume":"8","author":"Ke","year":"2021","unstructured":"Ke Y, Dai X, Xu D, Liang J, Yu Y, Cao H, Chen W and Lin J. Features and outcomes of elderly rheumatoid arthritis: does the age of onset matter? A comparative study from a single center in China. Rheumatol Ther 2021; 8: 243-254.","journal-title":"Rheumatol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O&#x2019","year":"2013","unstructured":"O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S and Keystone; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369: 307-318.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard-2023-223977","article-title":"Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial","volume":"82","author":"Almayali","year":"2023","unstructured":"Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, Da Silva JA, Griep E, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Lems W, Smulders Y, Cutolo M and Ter Wee MM. Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis 2023; 82: 1307-1314.","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS and Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303-2311.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","unstructured":"Croft M, Salek-Ardakani S and Ware CF. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov 2024; 23: 939-961.","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieslak D, Graham D, Wang C, Menon S, Hendrikx T and Kanik KS. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017; 377: 1537-1550.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.2019.16275","article-title":"Adalimumab and the challenges for biosimilars","volume":"322","author":"Gellad","year":"2019","unstructured":"Gellad WF and Good CB. Adalimumab and the challenges for biosimilars. JAMA 2019; 322: 2171-2172.","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"IB","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S and Pricop L; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496-1505.","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/ard-2024-226350","article-title":"Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the miracle trial","volume":"84","author":"Tamai","year":"2025","unstructured":"Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, Hirata S, Okano Y, Sato S, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Nishi Y, Mori M, Miyagishi H, Toshima G, Sato Y, Tsai WC, Takeuchi T and Kaneko Y; MIRACLE Study Group. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the miracle trial. Ann Rheum Dis 2025; 84: 41-48.","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","unstructured":"Fleischmann RM, Blanco R, Hall S, Thomson GTD, Van den Bosch FE, Zerbini C, Bessette L, Enejosa J, Li Y, Song Y, DeMasi R and Song IH. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis 2021; 80: 432-439.","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/art.43105","article-title":"Immune aging in rheumatoid arthritis","volume":"77","author":"Weyand","year":"2025","unstructured":"Weyand CM and Goronzy JJ. Immune aging in rheumatoid arthritis. Arthritis Rheumatol 2025; 77: 792-804.","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV predictra study","volume":"79","author":"Emery","year":"2020","unstructured":"Emery P, Burmester GR, Naredo E, Sinigaglia L, Lagunes I, Koenigsbauer F and Conaghan PG. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV predictra study. Ann Rheum Dis 2020; 79: 1023-1030.","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Morgan AW, Wilson AG, Hyrich KL, Isaacs J and Barton A. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet 2015; 385 Suppl 1: S48.","DOI":"10.1016\/S0140-6736(15)60363-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Misa-Garcia A, Ferro-Rodriguez S, Haro-Martin L and Cavero-Redondo I. Influence of volume and citrate on perceived pain in patients treated with adalimumab. Eur J Hosp Pharm 2025; [Epub ahead of print].","DOI":"10.1136\/ejhpharm-2024-004379"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2020-217209","article-title":"Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study","volume":"80","author":"Pappas","year":"2021","unstructured":"Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S and Kremer JM. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis 2021; 80: 96-102.","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S and Smolen JS; ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017; 390: 457-468.","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L and Fleischmann R. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016; 388: 2763-2774.","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S and Tanaka Y. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376: 652-662.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"JS","year":"2022","unstructured":"Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY and Fleischmann RM; CREDO2 Group. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2022; 387: 715-726.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/11\/ajtr0166235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:31:37Z","timestamp":1779442297000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/11\/ajtr0166235.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wdog7321","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}